GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CNTA
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Centessa Pharmaceuticals Limited stock upgraded to Sell Candidate.
(Updated on Apr 19, 2024)

Sell candidate since Apr 12, 2024 Loss -6.63% PDF

The Centessa Pharmaceuticals Limited stock price gained 0.380% on the last trading day (Friday, 19th Apr 2024), rising from $10.53 to $10.57. During the last trading day the stock fluctuated 3.90% from a day low at $10.26 to a day high of $10.66. The price has fallen in 5 of the last 10 days and is down by -1.67% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 41 thousand more shares were traded than the day before. In total, 149 thousand shares were bought and sold for approximately $1.57 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $10.08 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 33.55% during the next 3 months and, with a 90% probability hold a price between $13.47 and $17.65 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CNTA Signals & Forecast

Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Centessa Pharmaceuticals Limited stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $10.98 and $11.02. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, March 22, 2024, and so far it has fallen -13.36%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). The stock had a Golden Star Signal on Wednesday, December 13, 2023 in the long-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.

Buy
Special Signal Notification

Golden Star 12 Months

The stock had a Golden Star Signal on Wednesday, December 13, 2023 in the long-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.

Support, Risk & Stop-loss for Centessa Pharmaceuticals Limited stock

On the downside, the stock finds support just below today's level from accumulated volume at $9.26 and $8.15. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Centessa Pharmaceuticals Limited finds support just below today's level at $9.26. If this is broken, then the next support from accumulated volume will be at $8.15 and $8.01.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.400 between high and low, or 3.90%. For the last week, the stock has had daily average volatility of 5.29%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (CNTA) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect Centessa Pharmaceuticals Limited to open at $10.50, and during the day (based on 14 day Average True Range), to move between $9.85 and $11.29, which gives a possible trading interval of +/-$0.725 (+/-6.86%) up or down from last closing price. If Centessa Pharmaceuticals Limited takes out the full calculated possible swing range there will be an estimated 13.72% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $10.75 (1.70%) than the support at $9.26 (12.39%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Centessa Pharmaceuticals Limited stock A Buy?

The Centessa Pharmaceuticals Limited stock holds several negative signals and despite the positive trend, we believe Centessa Pharmaceuticals Limited will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

Current score: -4.201 Sell Candidate Upgraded

Predicted Opening Price for Centessa Pharmaceuticals Limited of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$10.50 ( 0.694%) $10.57

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CNTA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.90 3.09 %
R2 10.74 1.64 %
R1 10.65 0.752 %
Current price: 10.57
Support S1 10.34 -2.14 %
S2 10.25 -3.03 %
S3 10.10 -4.48 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 11.75 11.16 %
R2 10.83 2.46 %
R1 10.75 1.70 %
Current price 10.57
Support S1 9.26 -12.39%
S2 8.15 -22.89%
S3 8.01 -24.22%

FAQ

What is the symbol for Centessa Pharmaceuticals Limited Stock and on which exchange is it traded?
The symbol for Centessa Pharmaceuticals Limited is CNTA and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Centessa Pharmaceuticals Limited Stock?
The Centessa Pharmaceuticals Limited stock holds several negative signals and despite the positive trend, we believe Centessa Pharmaceuticals Limited will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

How to buy Centessa Pharmaceuticals Limited Stock?
Centessa Pharmaceuticals Limited Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Centessa Pharmaceuticals Limited Stock.

What's the current price of Centessa Pharmaceuticals Limited Stock?
As of the end of day on the 2024-04-19, the price of an Centessa Pharmaceuticals Limited (CNTA) share was $10.57.

What is the 52-week high and low for Centessa Pharmaceuticals Limited Stock?
The 52-week high for Centessa Pharmaceuticals Limited Stock is $12.41 and the 52-week low is $3.96.

What is the market capitalization of Centessa Pharmaceuticals Limited Stock?
As of the 2024-04-19, the market capitalization of Centessa Pharmaceuticals Limited is 1.044B.

When is the next earnings date for Centessa Pharmaceuticals Limited?
The upcoming earnings date for Centessa Pharmaceuticals Limited is May 10, 2024.
Click to get the best stock tips daily for free!

About Centessa Pharmaceuticals Limited

Centessa Pharmaceuticals Limited Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatm... CNTA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT